Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension

Journal of Human Hypertension

Volumn 14, Issue , 2000, Pages S73-S86

  Israili, Zafar H ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Angiotensin receptor blockers; Candesartan; Eprosartan; Irbesartan; Losartan; Pharmacokinetics; Telmisartan; Valsartan

Indexed keywords

2 [[5 ETHYL 3 [[2' (1H TETRAZOL 5 YL)BIPHENYL 4 YL]METHYL] 1,3,4 THIADIAZOLIN 2 YLIDENE]CARBAMOYL] 1 CYCLOPENTENECARBOXYLIC ACID; 2 BUTYL 1 [4 (6 CARBOXY 2,5 DICHLOROBENZOYLAMINO)BENZYL] 6 [N (METHYLAMINOCARBONYL) N PENTYLAMINO]BENZIMIDAZOLE; 2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; 4 PENTAFLUOROETHYL 2 PROPYL 1 [[2' (1H TETRAZOL 5 YL)BIPHENYL 4 YL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; 4' [(2 CYCLOPROPYL 7 METHYL 3H IMIDAZO[4,5 B]PYRIDIN 3 YL)METHYL][1,1' BIPHENYL] 2 CARBOXYLIC ACID; ABITASARTAN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BIBS 39; BMS 183920; CANDESARTAN; CANDESARTAN HEXETIL; CGP 48369; ELISARTAN; EMBUSARTAN; EPROSARTAN; FONSARTAN; FORASARTAN; GR 117289 C; IRBESARTAN; KR 31080; L 158 809; L 163 017; LOSARTAN; LRB 081; MILFASARTAN; OLMESARTAN; SAPRISARTAN; TELMISARTAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALSARTAN;

CLINICAL TRIAL; CONFERENCE PAPER; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIASTOLE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG PROTEIN BINDING; FATIGUE; HEADACHE; HEART DISEASE; HEART LEFT VENTRICLE HYPERTROPHY; HEART PROTECTION; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPERTENSION; KIDNEY FUNCTION; MICROALBUMINURIA; MUSCLE CRAMP; STRUCTURE ACTIVITY RELATION; UPPER RESPIRATORY TRACT INFECTION;

ADMINISTRATION, ORAL; ANTIHYPERTENSIVE AGENTS; BIOLOGICAL AVAILABILITY; BLOOD PRESSURE; HYPERTENSION; LOSARTAN; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2; RECEPTORS, ANGIOTENSIN;

EID: 0034088314     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/sj.jhh.1000991     Document Type: Article

References (172)

1. Timmermans PBMWM et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Revs 1993; 45: 205-251.
2. Carr AA, Prisant LM, Losartan. First of a new class of angiotensin antagonists for the management of hypertension. J Clin Pharmacol 1996; 36: 3-12.
3. Goa KL, Wagstaff AJ. Losartan potassium: a review of its pharmacology, clinical efficacy and tolerability in the management of hypertension. Drugs 1996; 51: 820-845. [Erratum: Drugs 1996; 52: 540].
4. Mallion JM, Goldberg AI. Global efficacy and tolerability of losartan, an angiotensin II subtype 1-receptor antagonist, in the treatment of hypertension. Blood Press 1996; 2: 82-86.
5. Ogihara T, Arakawa K. Clinical efficacy and tolerability of candesartan cilexetil. Candesartan Study Groups in Japan. J Hum Hypertens 1999; 13 (1): S27-S31.
6. Gillis JC, Markham A. Irbesartan. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in management of hypertension. Drugs 1997; 54: 885-902.
7. Man in’t Veld AJ. Clinical overview of irbesartan: expanding the therapeutic window in hypertension. J Hypertens 1997; 15: S27-S33.
8. Markham A, Goa KL. Valsartan. A review of its pharmacology and therapeutic use in essential hypertension. Drugs 1997; 54: 299-311.
9. McIntyre M, Caffe SE, Michalak RA, Reid JL. Losartan, an orally active angiotensin (ATI) receptor antagonist: a review of its efficacy and safety in essential hypertension. Pharmacol Ther 1997; 74: 181-194.
10. Pouleur HG. Clinical overview of irbesartan: a new angiotensin II receptor antagonist. Am J Hypertens 1997; 10 (Suppl): 318S-324S.
11. McClellan KJ, Balfour JA. Eprosartan. Drugs 1998; 55: 713-718; Discussion 719-720.
12. McClellan KJ, Goa KL. Candesartan cilexetil: a review of its use in essential hypertension. Drugs 1998; 56: 847-869.
13. McClellan KJ, Markham A. Telmisartan. Drugs 1998; 55: 1039-1044; Discussion 1045-1046.
14. Goodfriend TL, Elliott ME, Catt KJ. Angiotensin receptors and their antagonists. N Engl J Med 1996; 334: 1649-1654.
15. Timmermans PBMWM. Receptors. Am J Hypertens 1998; 11: 240A.
16. Ohtawa M et al. Pharmacokinetics and biochemical efficacy after single and multiple oral administration of losartan, an orally active nonpeptide angiotensin II receptor antagonist, in humans. Br J Clin Pharmacol 1993; 35: 290-297.
17. Grossman E et al. Hemodynamic and humoral effects of the angiotensin II antagonist losartan in essential hypertension. Am J Hypertens 1994; 7: 1041-1044.
18. Ogihara T et al. Effects of the angiotensin II receptor antagonist, TCV-116, on blood pressure and the renin-angiotensin system in healthy subjects. Clin Ther 1994; 16: 74-86.
19. Goldberg AI, Dunlay MC, Sweet CS. Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin converting enzyme inhibitors for the treatment of systemic hypertension. Am J Cardiol 1995; 25: 1345-1350.
20. Himmelmann A et al. Losartan in essential hypertension: effects on blood pressure and left ventricular mass. High Blood Press 1995; 4: 242-248.
21. van der Meiracker AH et al. Hemodynamic and biochemical effects of the ATa receptor antagonist irbesar-tan in hypertension. Hypertension 1995; 25: 22-29.
22. Byyny RL. Antihypertensive efficacy of the angiotensin II ATI-receptor antagonist losartan: results of a randomized, double-blind, placebo-controlled, parallel-group trial using 24-hour blood pressure monitoring. Ambulatory Blood Pressure Monitoring Study Group. Blood Press 1996; 2: 71-77.
23. Holwerda NJ et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enala-pril. J Hypertens 1996; 14: 1147-1151.
24. Sasaki M et al. Clinical pharmacology of multi-dose losartan, an angiotensin II receptor antagonist, in patients with essential hypertension. J Clin Pharmacol 1996; 36: 403-408.
25. Brunner HR. The new angiotensin II receptor antagonist, irbesartan: pharmacokinetic and pharmacodynamic considerations. Am J Hypertens 1997; 10: 311S-317S.
26. Burrell LM. A risk-benefit assessment of losartan potassium in the treatment of hypertension. Drug Safety 1997; 16: 56-65.
27. Chan P. Antihypertensive and antialbuminuric effects of losartan potassium and felodipine in Chinese elderly hypertensive patients with or without non-insulin-dependent diabetes mellitus. Am J Nephrol 1997; 17: 72-80.
28. Elmfeldt D, George M, Hübner R, Olofsson B. Candes-artan cilexetil, a new generation angiotensin II antagonist, provides dose dependent antihypertensive effect. J Hum Hypertens 1997; 11 (2): S49-S53.
29. Heuer J, Schondorfer G, Hogemann AM. Twenty-four hour blood pressure profile of different doses of cande-sartan cilexetil in patients with mild to moderate hypertension. J Hum Hypertens 1997; 11 (2): S55-S56.
30. Ruilope L. Human pharmacokinetic/pharmaco-dynamic profile of irbesartan: a new potent angiotensin II receptor antagonist. J Hypertens 1997; 15: S15-S20.
31. Sever PS. Clinical profile of the novel angiotensin II type I blocker candesartan cilexetil. J Hypertens 1997; 15: S9-S12.
32. Biagini M. Effects of losartan on 24-hour blood pressure and its variability in mild to moderate hypertension [abstract]. Am J Hypertens 1998; 11: 262A.
33. Fernández-Andrade C. A randomized, doubleblind, parallel study of the safety and antihypertensive efficacy of losartan vs amlodipine in patients with mild to moderate hypertension and impaired renal function [abstract]. Am J Hypertens 1998; 11: 120A.
34. Fridman K, Wysocki M, Friberg P, Andersson O. Longterm effects of candesartan cilexetil on the systemic and renal haemodynamics in moderately hypertensive patients [abstract]. Am J Hypertens 1998; 11: 77A.
35. Guthrie R et al, for the Irbesartan Multicenter Study Group. Long-term safety with irbesartan and hydrochlorothiazide in hypertension [abstract]. Am J Hypert-ens 1998; 11: 45A.
36. Hall J et al. Long term safety and efficacy of valsartan [abstract]. Am J Hypertens 1998; 11: 74A.
37. Kassler-Taub KB et al, for the Irbesartan/Losartan Study Investigators. Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan, in mild-to-moderate hypertension. Am J Hypertens 1998; 11: 445-453; Comments: Am J Hypertens 1999; 12: 79-81.
38. Lacourcière Y, and the Telmisartan Blood Pressure Monitoring Group. A comparison of the blood pressure profile of telmisartan and losartan at 18-24 hours postdosing as measured by ambulatory blood pressure monitoring [abstract]. Am J Hypertens 1998; 11: 262A.
39. Marino MR, Langenbacher KM, Ford NF, Uderman HD. Pharmacokinetics and pharmacodynamics of irbesartan in healthy subjects. J Clin Pharmacol 1998; 38: 246-255.
40. Meilenbrock S, Oddou-Stock P, Brenner A. Long-term efficacy and tolerability of Diovan® in elderly hypertensive patients compared with lisinopril [abstract]. Am J Hypertens 1998; 11: 73A.
41. Mimran A et al. A randomized, double-blind comparison of the angiotensin II receptor antagonist, irbesartan, with full dose range of enalapril for the treatment of mild-to-moderate hypertensin. J Hum Hypertens 1998; 12: 203-208.
42. Oparil S et al, on behalf of the Irbesartan/Losartan Study Investigators. An elective-titration study of the comparative effectiveness of two angiotensin Il-recep-tor blockers, irbesartan and losartan. Clin Ther 1998; 20: 398-409.
43. Plum J, Bunten B, Nemeth R, Grabensee B. Effects of angiotensin II antagonist valsartan on blood pressure, proteinuria, and renal hemodynamics in patients with chronic renal failure and hypertension. J Am Soc Nephrol 1998; 9: 2223-2234.
44. Pool JL et al. Dose-related antihypertensive effects of irbesartan in patients with mild-to-moderate hypertension. Am J Hypertens 1998; 11: 462-470.
45. Smith RD, Aurup P, Goldberg AI, Snavely D. Long term safety of losartan in open label trials in patients with mild to moderate essential hypertension [abstract]. Am J Hypertens 1998; 11: 43A.
46. Tedesco MA et al. Effects of losartan on hypertension and left ventricular mass: a long-term study. J Hum Hypertens 1998; 12: 505-510; Comments: J Hum Hypertens 1998; 12: 493-495.
47. Bell TP et al, for the Candesartan Cilexetil Study Investigators. Effective dose range of candesartan cilexetil for systemic hypertension. Candesartan cilexetil Study Investigators. Am J Cardiol 1999; 83: 272-275.
48. Bremner A et al. Long-term efficacy and safety of valsartan in 823 mild to moderate hypertensives [abstract]. Am J Hypertens 1999; 12: 127A.
49. Gavras I, Gavras H. Safety and tolerability of eprosar-tan. Pharmacotherapy 1999; 19: 102S-107S.
50. Karlberg BE, Lins LE, Hermansson K. Efficacy and safety of telmisartan, a selective ATI receptor antagonist, compared with enalapril in elderly patients with primary hypertension. TEES Study Group. J Hypertens 1999; 17: 293-302.
51. Lacourciere Y, Asmar R, on behalf of the CHAMP study group. Comparison of the effects of candesartan and losartan on ambulatory blood pressure in patients with essential ambulatory hypertension. A forced titration study [abstract]. Am J Hypertens 1999; 12: 41A.
52. Martinez F, Oigman W, Parra Carillo J, Michieletto L, and valsartan Latam Investigator Group. Tolerability and antihypertensive efficacy of valsartan over 24 hours compared to nifedipine retard [abstract]. Am J Hypertens 1999; 12: 126A.
53. Papademetriou V, Michelson EL. Efficacy and tolerability of the combination of candesartan cilexetil and hydrochlorothiazide in systemic hypertension [abstract]. Am J Hypertens 1999; 12: 126A.
54. Weber M. Clinical efficacy of eprosartan. Pharmacotherapy 1999; 19: 95S-101S.
55. Black H, Reed J, Fitzsimmons S, Shi Y. The combination of valsartan and hydrochlorothiazide is effective and well tolerated in essential hypertension [abstract]. Am J Hypertens 1998; 11: 71A.
56. Neutel JM, Smith DHG. Dose response and antihypertensive efficacy of the ATa receptor antagonist telmis-artan in patients with mild to moderate hypertension. Adv Therap 1998; 15: 206-217.
57. Hedner T et al. A comparison of the angiotensin II antagonists valsartan and losartan in the treatment of essential hypertension. Am J Hypertens 1999; 12: 414-417.
58. Smith DHG, Neutel JM, Morgenstern P. Once-daily tel-misartan compared with enalapril in the treatment of hypertension. Adv Therap 1998; 15: 229-240.
59. Marino MR et al. Pharmacokinetics and pharmacodynamics of irbesartan in patients with hepatic cirrhosis. J Clin Pharmacol 1998; 38: 347-356.
60. Zuschke CA et al. Candesartan cilexetil: comparison of once-daily versus twice-daily administration for systemic hypertension. Candesartan Study Investigators. Clin Ther 1999; 21: 464-74.
61. Harland D et al. Safety of eprosartan in elderly patients with hypertension [abstract]. Am J Hypertens 1998; 11: 78A.
62. Dickstein K et al. Hemodynamic and neurohumoral effects of the angiotensin II antagonist losartan in patients with heart failure. J Hypertens 1994; 12: S31-S35.
63. Messerli FH, Weber MA, Brunner HR. Angiotensin II receptor inhibition: a new therapeutic approach. Arch Intern Med 1996; 156: 1957-1965.
64. Pitt B et al. Rationale, background, and design of the Randomized Angiotensin receptor antagonist-Angiotensin-converting enzyme inhibitor Study (RAAS). Am J Cardiol 1996; 78: 1129-1131.
65. Lang RM et al. Comparative effects of losartan and enalapril on exercise capacity and clinical status in patients with heart failure. The Losartan Pilot Exercise Study Investigators. J Am Coll Cardiol 1997; 30: 983-991.
66. Pitt B et al, on behalf of the ELITE Study Investigators. Randomized trial of losartan versus captopril in patients over 65 with heart failure Evaluation of Losartan in The Elderly study (ELITE) trial. Lancet 1997; 349: 747-752.
67. van Zwieten PA. Current and newer approaches in the drug treatment of congestive heart failure. Cardiovasc Drugs Ther 1997; 10: 693-702.
68. Yusuf S, Maggioni AP, Held P, Rouleau J-L. Effects of candesartan, enalapril or their combination on exercise capacity, ventricular function, clinical deterioration and quality of life in heart failure: Randomized Evaluation of Strategies for Left Ventricular Dysfunction (Resolved). Circulation 1997; 96 (1): 1-452.
69. Aronow WS. The ELITE Study. What are its implications for the drug treatment of heart failure? Evaluation of Losartan in the Elderly Study. Drugs Aging 1998; 12: 423-428.
70. Vijay N et al. Irbesartan Heart failure Group. Irbesartan compared with lisinopril in patients with mild to moderate heart failure [abstract]. Am J Coll Cardiol 1998; 31: 68A.
71. Brunner-La Rocca HP. Recent insights into therapy of congestive heart failure: focus on ACE inhibitors and angiotensin II antagonist. J Am Coll Cardiol 1999; 33: 1163-1173.
72. Granger C et al. On behalf of SPICE Investigators. A randomized trial evaluating tolerability of candesartan for patients with congestive heart failure and intolerance to angiotensin converting enzyme inhibitors [abstract]. J Am Coll Cardiol 1999; 33: 189A.
73. Havranek EP et al, for the Irbesartan Heart Failure Group. Dose-related beneficial long-term hemodynamic and clinical efficacy of irbesartan in heart failure. J Am Coll Cardiol 1999; 33: 1174-1181.
74. Farsang C et al, for the Losartan ISH Trial Investigators Group. Losartan treatment of patients with isolated systolic hypertension [abstract]. Am JHypertens 1999; 12: 140A.
75. Larochelle P et al. Effects and tolerability of irbesartan versus enalapril in patients with severe hypertension. Irbesartan Multicenter Investigators. Am J Cardiol 1997; 80: 1613-1615.
76. Oparil S, Ripley E. Candesartan Cilexetil enhances blood pressure reduction in severe (Stage 3, JNC-VI) hypertensive patients inadequately controlled with HCTZ [abstract]. Am J Hypertens 1998; 11: 121A.
77. Ripley E, Oparil S. The addition of candesartan cilexetil to HCTZ enhances blood pressure reduction in black patients with severe (Stage 3, JNC-VI) hypertension [abstract]. Am J Hypertens 1998; 11: 119A.
78. Oparil S, Michelson EL, for the Candesartan Cilexetil Study Investigators. Effects of Candesartan cilexetil in patients with severe hypertension [abstract]. J Am Coll Cardiol 1999; 33: 299A.
79. Goldberg MR, Bradstreet TE, Tanaka WK, Bjornsson TD. Biochemical response to angiotensin receptor blockade in hypertensive patients [abstract]. Clin Pharmacol Ther 1994; 55: 205.
80. Trenkwalder P, Dahl K, Lehtovirta M, Mulder H, Long term treatment with candesartan cilexetil does not affect glucose homeostasis or serum lipid profile in patients with mild hypertension and type II diabetes [abstract]. Am J Hypertens 1997; 10: 85A.
81. Trenkwalder P. Effect of candesartan cilexetil on glucose homeostasis. Multicenter Study Group. Basic Res Cardiol 1998; 93 (2): 140-144.
82. Ilson BE et al. Renal hemodynamic effects of SK&F 108566, a nonpeptide selective angiotensin receptor ATI antagonist [abstract]. Clin Pharmacol Ther 1994; 55: 206.
83. Kawabata M et al. Effects of an angiotensin II receptor antagonist, TCV-116, on renal haemodynamics in essential hypertension. Blood Press 1994; 5: 117-121.
84. Fauvel JP et al. Effects of losartan on renal function in patients with essential hypertension. J Cardiovasc Pharmacol 1996; 28: 259-263.
85. Buter H, Navis G, de Zeeuw D, de Jong PE. Renal hemodynamic effects of candesartan in normal and impaired renal function in humans. Kidney Int Suppl. 1997; 63: S185-S187.
86. Ilson BE et al. A dose-response study to assess the renal hemodynamic, vascular, and hormonal effects of eprosartan an angiotensin II AT1-receptor antagonist, in sodium-replete healthy men. Clin Pharmacol Ther 1998; 63: 471-481.
87. Mann JF. Valsartan and the kidney: present and future. J Cardiovasc Pharmacol 1999; 33 (1): S37-S40.
88. Stettin G et al. One-year persistency and compliance with 5 major classes of antihypertensive therapy [abstract], Clin Pharmacol Ther 1998; 63: 197.
89. Bossini A et al. Losartan induces LVMI reduction, better if combined to ACE-inhibitors? One year follow-up [abstract]. Am J Hypertens 1998; 11: 127A.
90. Kahan T et al. Rate and extent of left ventricular hypertrophy regression: a comparison of angiotensin II blockade with irbesartan and beta-blockade. J Am Coll Cardiol 1998; 31 (A): 857-864.
91. Lonati L et al. The effect of losartan on left ventricular mass in hypertensive patients. Double-blind comparison study with verapamil [abstract]. Am J Hypertens 1998; 11: 119A.
92. Thurmann PA et al. Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension. Circulation 1998; 98: 2037-2042; Comments in Circulation 1998; 98: 1987-1989.
93. Rosendorff C. The renin-angiotensin system and vascular hypertrophy. J Am Coll Cardiol 1996; 28: 803-812.
94. Ayoub JCA et al. Losartan improves diastolic function of hypertensive patients [abstract]. Am J Hypertens 1998; 11: 129A.
95. Crippa M et al. Angiotensin II-receptor ATa blockade reduces ventricular arrhythmias in uncomplicated essential hypertensive patients [abstract]. Am J Hypertens 1998; 11: 40A.
96. Lim PO et al. Irbesartan reduces QT dispersion in hypertensive individuals. Hypertension 1999; 33: 713-718.
97. Calvo C et al. Irbesartan and atorvastatin improves endothelial function in hypertensive and hyperchole-sterolemic men [abstract]. Hypertension 1999; 33: 1070.
98. Russo D et al. The blockade of angiotensin II but not the reduction of systolic blood pressure reduces proteinuria in patients with IgA nephropathy [abstract]. Am J Hypertens 1998; 11: 44A.
99. Muirhead N et al. Valsartan (Diovan_): effect on microalbuminuria in patients with type II diabetes and nephropathy [abstract]. J Am Coll Cardiol 1999; 33: 299A.
100. Moan A et al. Effects of losartan on insulin sensitivity in severe hypertension: connections through sympathetic nervous system activity? J Hum Hypertens 1995; 9 (5): S45-S50.
101. Higashiura K, Ura N, Miyazaki Y, Shimamoto K. Effect of angiotensin II receptor antagonist, candesar-tan, on insulin resistance and pressor mechanism in essential hypertension. J Hum Hypertens 1999; 12 (1): S71-S74.
102. Ilson BE, Martin DE, Boike SC, Jorkasky DK. The effect of eprosartan, an angiotensin II ATa receptor antagonist, on uric acid excretion in patients with mild to moderate essential hypertension. J Clin Pharmacol 1998; 38: 437-441.
103. Minghelli G, Seudoux C, Goy JJ, Burnier M. Uricosuric effect of the angiotensin II receptor antagonist losartan in heart transplant recipients. Transplantation 1998; 66: 268-271.
104. Tavares A et al. Acute and chronic effects of losartan upon uric acid levels and urine pH in hypertensive patients [abstract]. Hypertension 1999; 33: 1093.
105. Ward H, Pan D. Raised serum uric acid levels are associated with increased risk for stroke and heart attack [abstract]. Am J Hypertens 1999; 12: 88A.
106. Munafo A et al. Drug concentration response relationships in normal volunteers after oral adminis-tration of losartan, an angiotensin II receptor antagonist. Clin Pharmacol Ther 1992; 51: 513-521.
107. Hoogkamer JF et al. Pharmacokinetics and safety of candesartan cilexetil in subjects with normal and impaired liver function. Eur J Clin Pharmacol 1998; 54: 341-345.
108. Marino MR, Langenbacher KM, Ford NF, Uderman HD. Safety, tolerability, pharmacokinetics and pharmacodynamics of irbesartan after single and multiple doses in healthy male subjects [abstract], Clin Pharmacol Ther 1997; 61: 207.
109. Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme therapy. Ann Intern Med 1992; 117: 234-242.
110. Sharma PK, Yium JJ. Angioedema associated with angiotensin II receptor antagonist losartan. South Med J 1997; 90: 552-553.
111. Acker CG, Greenberg A. Angioedema induced by the angiotensin II blocker losartan [letter], N Engl J Med 1995; 333:1572.
112. Frye GB. Pettigrew TJ. Angioedema and photosensitive rash induced by valsartan. Pharmacotherapy 1998; 18: 866-868.
113. van Rijnsoever EW, Kwee-Zuiderwijk WJ, Feenstra J. Angioneurotic edema attributed to the use of losartan. Arch Intern Med 1998; 158: 2063-2065.
114. Rupprecht R, Vente C, Grafe A, Fuchs T. Angioedema due to losartan. Allergy 1999; 54: 81-82.
115. Dingemanse J et al. Comparative pharmacokinetics of multiple-dose candesartan in subjects with and without impaired hepatic function [abstract], Clin Pharmacol Ther 1997; 61: 209.
116. Tenero DM et al. Pharmacokinetics of intravenously and orally administered eprosartan in healthy males: absolute bioavailability and effect of food. Biopharm Drug Dispos 1998; 19: 351-356.
117. Bottorff MD, Tenero DM. Pharmacokinetics of eprosartan in healthy subjects, patients with hypertension, and special populations. Pharmacotherapy 1999; 19: 73S-78S.
118. Martin DE et al. Pharmacokinetics and protein binding of eprosartan in healthy male volunteers and in patients with varying degrees of renal impairment. J Clin Pharmacol 1998; 38: 129-137.
119. Ilson BE et al. Food significantly increases the oral bioavailability of SK&F 108566 [abstract], Clin Pharmacol Ther 1994; 55: 168.
120. Chapelsky MC et al. A dose proportionality study of eprosartan in healthy male volunteers. J Clin Pharmacol 1998; 38: 34-39.
121. Tenero DM et al. Effect of hepatic disease on the pharmacokinetics and plasma protein binding of eprosartan. Pharmacotherapy 1998; 18: 42-50.
122. Kazierad DJ et al. Effect of fluconazole on the pharmacokinetics of eprosartan and losartan in healthy male volunteers. Clin Pharmacol Ther 1997; 62: 417-425.
123. Cox PJ et al. The metabolic fate of eprosartan in healthy subjects. Exp Toxicol Pathol 1996; 48: 340-341.
124. Vachharajani NN et al. Oral bioavailability and disposition characteristics of irbesartan, an angiotensin antagonist, in healthy volunteers. J Clin Pharmacol 1998; 38: 702-707.
125. Vachharajani NN et al. Lack of effect of food on the oral bioavailability of irbesartan in healthy male volunteers. J Clin Pharmacol 1998; 38: 433-436.
126. Marino MR et al. Effect of hydrochlorothiazide on the pharmacokinetics and pharmacodynamics of irbesartan [abstract], Clin Pharmacol Ther 1997; 61: 207.
127. Kovacs SJ, Wilton JH, Blum RA. Steady state pharmacokinetics of irbesartan alone and in combination with fluconazole [abstract]. Clin Pharmacol Ther 1999; 65: 132.
128. Bourrie M, Meunier V, Berger Y, Fabre G. Role of cytochrome P-4502C9 in irbesartan oxidation by human liver microsomes. Drug Metab Dispos 1999; 27: 288-296.
129. Chando TJ et al. Biotransformation of irbesartan in man. Drug Metab Dispos 1998; 26: 408-417.
130. Nakashima M, Umemura K. The clinical pharmacology of losartan in Japanese subjects and patients. Blood Press 1996; 2: 62-66.
131. Lo M-W et al. Pharmacokinetics of intravenous and oral losartan in patients with heart failure. J Clin Pharmacol 1998; 38: 525-532.
132. Lo M-W et al. Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans. Clin Pharmacol Ther 1995; 58: 641-649.
133. Christ DD. Human plasma protein binding of the angiotensin II receptor antagonist losartan potassium (DuP 753/MK 954) and its pharmacologically active metabolite EXP3174. J Clin Pharmacol 1995; 35: 515-520.
134. Williamson KM et al. Effects of erythromycin or rifampin on losartan pharmacokinetics in healthy volunteers. Clin Pharmacol Ther 1998; 63: 316-323.
135. Lo M-W et al. Pharmacokinetics of losartan (MK-954 or DuP 753) in patients with renal insufficiency [abstract], Clin Pharmacol Ther 1993; 53: 160.
136. Yun CH et al. Oxidation of the angiotensin II receptor antagonist losartan (DuP 753) in human liver microsomes. Role of cytochrome P4503A(4) in formation of the active metabolite EXP3174. Drug Metab Dispos 1995; 23: 285-289.
137. Stearns RA, Chakravarty PK, Chen R, Chiu SHL. Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes. Role of cytochrome P4502C and 3A subfamily members. Drug Metab Dispos 1995; 23: 207-215.
138. Stangier J, Schmid J, Tiirck D. Pharmacokinetics of [14C]-radiolabelled telmisartan, a potent angiotensin II antagonist in healthy male subjects. 1st International Symposium on Angiotensin II Antagonism. 1997, 28 Sept-1 Oct, London.
139. Busch J, Heinzel G, Roth W. Animal pharmacokinetics of telmisartan and their application to man. 1st International Symposium on Angiotensin II Antagonism. 1997, 28 Sept-1 Oct, London.
140. Neutel JM, Smith DHG, for the Telmisartan U.S. Study Group. Dose response and pharmacokinetics of telmisartan, a new angiotensin II receptor blocker [abstract]. Am J Hypertens 1998; 11: 111A.
141. Schmid J et al. In vivo and in vitro biotransformation of telmisartan. 1st International Symposium on Angiotensin II Antagonism. 1997, 28 Sept-1 Oct, London.
142. Schmidt EK, Antonin KH, Flesch G, Racine-Poon A. An interaction study with cimetidine and the new angiotensin II antagonist valsartan. Eur f Clin Pharmacol 1998; 53: 451-458.
143. Flesch G, Muller P, Lloyd P. Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin II antagonist, in man. Eur f Clin Pharmacol 1997; 52: 115-120.
144. Midler P et al. Pharmacokinetic and pharmacodynamic effects of the angiotensin II antagonist valsartan at steady state in healthy, normotensive subjects. Eur J Clin Pharmacol 1997; 52: 441-449.
145. Colussi DM et al. Protein binding in plasma of valsartan, a new angiotensin II receptor antagonist. J Clin Pharmacol 1997; 37: 214-227.
146. Waldmeier F et al. Pharmacokinetics, distribution and biotransformation of 14C-radiolabeled valsartan in healthy male volunteers after a single dose. Xeno-biotica 1997; 27: 59-71.
147. Tenero DM et al. Effect of age and gender on the pharmacokinetics of eprosartan. Pharmacol 1998; 46: 267-270.
148. Vachharajani, Shyu WC et al. The effects of age and gender on the pharmacokinetics of irbesartan. Br Clin Pharmacol 1998; 46: 611-613.
149. Vachharajani, Shyu WC et al. Lack of effect of race on the pharmacokinetics of irbesartan [abstract]. Clin Pharmacol Ther 1997; 61: 160.
150. Marino MR, Vachharajani NN, for the Multicenter Investigators. The pharmacokinetics of irbesartan are not altered in special populations [abstract]. Am J Hypertens 1998; 11: 101A.
151. Sica DA et al. The pharmacokinetics of irbesartan in renal failure and maintenance hemodialysis. Clin Pharmacol Ther 1997; 62: 610-618.
152. Spielberg S et al. A mutation in CYP2C9 is responsible for decreased metabolism of losartan [abstract]. Clin Pharmacol Ther 1996; 59: 215.
153. McCrea JB et al. A rare deficiency of the conversion of losartan to its active metabolite E3174 [abstract]. Clin Pharmacol Ther 1995; 57: 154.
154. Brookman LJ et al. Pharmacokinetics of valsartan in patients with liver disease. Clin Pharmacol Ther 1997; 62: 272-278.
155. Martin DE et al. Lack of effect of eprosartan on the single dose pharmacokinetics of orally administered digoxin in healthy male volunteers. Br J Clin Pharmacol 1997; 43: 661-664.
156. Kazierad DJ et al. Eprosartan does not affect the pharmacodynamics of warfarin. J Clin Pharmacol 1998; 38: 649-653.
157. Martin DE et al. Eprosartan, an angiotensin II receptor antagonist, does not affect the pharmacodynamics of glyburide in patients with type II diabetes mellitus. J Clin Pharmacol 1997; 37: 155-159.
158. Tenero DM et al. Effect of ranitidine on the pharmacokinetics of orally administered eprosartan, an angiotensin II antagonist, in healthy male volunteers. Ann Pharmacother 1998; 32: 304-308.
159. Marino MR et al. Lack of effect of nifedipine on the pharmacokinetics and pharmacodynamics of irbesartan [abstract]. J Clin Pharmacol 1997; 37: 872.
160. Gielsdorf W, Mangold B, Marino MR. Pharmacokinetics and pharmacodynamics of warfarin given with irbesartan [abstract]. Clin Pharmacol Ther 1998; 63: 228.
161. De Smet M et al. Effect of multiple doses of losartan on the pharmacokinetics of single doses of digoxin in healthy volunteers. Br J Clin Pharmacol 1995; 40: 571-575.
162. Kong T et al. Losartan does not affect the pharmacokinetics and pharmacodynamics of warfarin. J Clin Pharmacol 1995; 35: 1008-1015.
163. McCrea JB et al. Absence of a pharmacokinetic interaction between losartan and hydrochlorothiazide. J Clin Pharmacol 1995; 35: 1200-1206.
164. McCrea JB et al. Ketoconazole does not effect the systemic conversion of losartan to E-3174 [abstract]. Clin Pharmacol Ther 1996; 59: 169.
165. Meadowcroft AM et al. The effects of fluvastatin, a CYP2C9 inhibitor, on losartan pharmacokinetics [abstract]. Clin Pharmacol Ther 1998; 63: 213.
166. Goldberg MR et al. Effects of cimetidine on pharmacokinetics and pharmacodynamics of losartan, and ATI-selective non-peptide angiotensin II receptor antagonist. Eur J Clin Pharmacol 1995; 49: 115-119.
167. Zaidenstein R et al. Effect of grapefruit juice on the pharmacokinetics of losartan in healthy volunteers [abstract]. Clin Pharmacol Ther 1999; 65: 132.
168. Kazierad DJ et al. Fluconazole significantly alters the pharmacokinetics of losartan but not eprosartan [abstract]. Clin Pharmacol Ther 1997; 61: 203.
169. Goldberg MR et al. Phenobarbital minimally alters plasma concentrations of losartan and its active metabolite E-3174. Clin Pharmacol Ther 1996; 59: 268-274.
170. Allen TL et al. In vivo inhibitory effect of phenytoin on losartan disposition [abstract]. Clin Pharmacol Ther 1999; 65: 149.
171. Su CAPF et al. Influence of telmisartan, a nonpeptide angiotensin II receptor antagonist, on steady state pharmacodynamics and pharmacokinetics of warfarin in healthy subjects [abstract]. Naunyn Schmiedeb-ergs Arch Pharmacol 1996; 353 (Suppl): R-155.
172. Prasad P, Mangat S, Yeh CM, Glazer R. Lack of pharmacokinetic interaction between valsartan and digoxin [abstract]. Am J Hypertens 1999; 12: 124A.